Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting
| Autor: | Neil Nagovski, J Hunter Lambert, Lucio N. Gordan, Stanley M. Marks, Robert E. Smith, Mei Xue |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Schedule Drug Administration Schedule Drug Costs medicine Humans In patient Dosing Treatment costs Multiple myeloma Aged Retrospective Studies Aged 80 and over business.industry Daratumumab Antibodies Monoclonal General Medicine Middle Aged medicine.disease Drug Utilization Progression-Free Survival United States Oncology Emergency medicine Cost analysis Costs and Cost Analysis Female Cost of care business Multiple Myeloma |
| Zdroj: | Future oncology (London, England). 18(3) |
| ISSN: | 1744-8301 |
| Popis: | Background: The introduction of daratumumab into the treatment of multiple myeloma has improved outcomes in patients; however, community oncologists often dose more frequently than the US FDA-approved label. Materials and methods: Integra analyzed its database to elucidate daratumumab treatment patterns and the impact of increased utilization on the cost of care for multiple myeloma. Results: Following week 24, 671 (65%) of 1037 patients remained on daratumumab-containing regimens, with 330 patients continuing more frequent treatments than the expected once-every-4-weeks dosing described in the standard dosing schedule. Patients received an average of 14% more daratumumab doses than the FDA-approved label indicates, increasing the 1-year daratumumab costs by an estimated US$31,353. Conclusion: Daratumumab is utilized more frequently than the FDA-recommended dosing, leading to higher multiple myeloma treatment costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|